User profiles for Viviane S. Boaventura
 | Viviane S. BoaventuraProfessora da Faculdade de Medicina da UFBA e Pesquisadora em saúde Pública da … Verified email at fiocruz.br Cited by 2053 |
[HTML][HTML] Vaccine effectiveness of heterologous CoronaVac plus BNT162b2 in Brazil
…, N Pearce, A Sheikh, M Barral-Netto, VS Boaventura - Nature Medicine, 2022 - nature.com
… credit to the original author(s) and the source, provide a … ’s Creative Commons license,
unless indicated otherwise in a credit line to the material. If material is not included in the article’s …
unless indicated otherwise in a credit line to the material. If material is not included in the article’s …
Human mucosal leishmaniasis: neutrophils infiltrate areas of tissue damage that express high levels of Th17‐related cytokines
VS Boaventura, CS Santos, CR Cardoso… - European journal of …, 2010 - Wiley Online Library
Mucosal leishmaniasis (ML) is characterised by severe tissue destruction. Herein, we
evaluated the involvement of the IL‐17‐type response in the inflammatory infiltrate of biopsy …
evaluated the involvement of the IL‐17‐type response in the inflammatory infiltrate of biopsy …
[HTML][HTML] Influence of age on the effectiveness and duration of protection of Vaxzevria and CoronaVac vaccines: A population-based study
…, V de Araújo Oliveira, VS Boaventura… - The Lancet Regional …, 2022 - thelancet.com
Background Aging influences COVID-19 severity and response to vaccination, but previous
vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within …
vaccine effectiveness (VE) analyzes lack the power to evaluate its role in subgroups within …
[HTML][HTML] Vaccine effectiveness of two-dose BNT162b2 against symptomatic and severe COVID-19 among adolescents in Brazil and Scotland over time: a test-negative …
…, GO Penna, SV Katikireddi, VS Boaventura… - The Lancet Infectious …, 2022 - thelancet.com
Background Little is known about vaccine effectiveness over time among adolescents,
especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the …
especially against the SARS-CoV-2 omicron (B.1.1.529) variant. This study assessed the …
Vaccination plus previous infection: protection during the omicron wave in Brazil
As of May 11, 2022, an estimated 519 million individuals have been infected with SARS-CoV-2,
and at least 11 billion COVID-19 vaccine doses were positive and defined as cases, and …
and at least 11 billion COVID-19 vaccine doses were positive and defined as cases, and …
[HTML][HTML] Duration of protection of CoronaVac plus heterologous BNT162b2 booster in the Omicron period in Brazil
…, N Pearce, ML Barreto, VS Boaventura… - Nature …, 2022 - nature.com
… credit to the original author(s) and the source, provide a … ’s Creative Commons license,
unless indicated otherwise in a credit line to the material. If material is not included in the article’s …
unless indicated otherwise in a credit line to the material. If material is not included in the article’s …
Arginase I, Polyamine, and Prostaglandin E2 Pathways Suppress the Inflammatory Response and Contribute to Diffuse Cutaneous Leishmaniasis
…, J Van Weyenbergh, VS Boaventura… - The Journal of …, 2015 - academic.oup.com
Diffuse cutaneous leishmaniasis (DCL) is a rare clinical manifestation of tegumentary
leishmaniasis. The molecular mechanisms underlying DCL pathogenesis remain unclear, and …
leishmaniasis. The molecular mechanisms underlying DCL pathogenesis remain unclear, and …
Effectiveness of CoronaVac, ChAdOx1 nCoV-19, BNT162b2, and Ad26. COV2. S among individuals with previous SARS-CoV-2 infection in Brazil: a test-negative …
…, JR Andrews, VS Boaventura… - The Lancet Infectious …, 2022 - thelancet.com
Background COVID-19 vaccines have proven highly effective among individuals without a
previous SARS-CoV-2 infection, but their effectiveness in preventing symptomatic infection …
previous SARS-CoV-2 infection, but their effectiveness in preventing symptomatic infection …
[HTML][HTML] Prevalence and risk factors for long COVID after mild disease: A cohort study with a symptomatic control group
…, A Barral, CG Barbosa, VS Boaventura - Journal of Global …, 2023 - ncbi.nlm.nih.gov
Background There is limited data on the prevalence and risk factors for long COVID and few
prospective studies with appropriate control groups and adequate sample sizes. We …
prospective studies with appropriate control groups and adequate sample sizes. We …
[HTML][HTML] Towards a More Precise Serological Diagnosis of Human Tegumentary Leishmaniasis Using Leishmania Recombinant Proteins
AP Souza, M Soto, JML Costa, VS Boaventura… - PLoS …, 2013 - journals.plos.org
Background Exposure to Leishmania induces a humoral immune response that can be used
as a marker of parasite exposure. Methodology/Principal Findings Herein, ELISA was used …
as a marker of parasite exposure. Methodology/Principal Findings Herein, ELISA was used …
